Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 5
2006 6
2007 3
2008 9
2009 9
2010 15
2011 15
2012 35
2013 29
2014 37
2015 28
2016 35
2017 33
2018 36
2019 39
2020 28
2021 18
2022 21
2023 23
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

398 results

Results by year

Filters applied: . Clear all
Page 1
Real-world persistence of multiple sclerosis disease-modifying therapies.
Tallantyre EC, Dobson R, Froud JLJ, St John FA, Anderson VM, Arun T, Buckley L, Evangelou N, Ford HL, Galea I, George S, Gray OM, Hibbert AM, Hu M, Hughes SE, Ingram G, Kalra S, Lim CE, Mathews JTM, McDonnell GV, Mescall N, Norris S, Ramsay SJ, Rice CM, Russell MJ, Shawe-Taylor MJ, Williams TE, Harding KE, Robertson NP. Tallantyre EC, et al. Among authors: robertson np. Eur J Neurol. 2024 Apr 3:e16289. doi: 10.1111/ene.16289. Online ahead of print. Eur J Neurol. 2024. PMID: 38567516
Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes.
Kodosaki E, Watkins WJ, Loveless S, Kreft KL, Richards A, Anderson V, Hurler L, Robertson NP, Zelek WM, Tallantyre EC. Kodosaki E, et al. Among authors: robertson np. J Neuroinflammation. 2024 Feb 17;21(1):52. doi: 10.1186/s12974-024-03036-4. J Neuroinflammation. 2024. PMID: 38368354 Free PMC article.
Prodromal multiple sclerosis: considerations and future utility.
Harding KE, Kreft KL, Ben-Shlomo Y, Robertson NP. Harding KE, et al. Among authors: robertson np. J Neurol. 2024 Apr;271(4):2129-2140. doi: 10.1007/s00415-023-12173-4. Epub 2024 Feb 11. J Neurol. 2024. PMID: 38341810 Free PMC article. Review.
Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
Brittain G, Petrie J, Duffy KEM, Glover R, Hullock K, Papaioannou D, Roldan E, Beecher C, Bursnall M, Ciccarelli O, Coles AJ, Cooper C, Giovannoni G, Gabriel I, Kazmi M, Kyriakou C, Nicholas R, Paling D, Peniket A, Scolding N, Silber E, de Silva T, Venneri A, Walters SJ, Young C, Muraro PA, Sharrack B, Snowden JA; StarMS trial team. Brittain G, et al. BMJ Open. 2024 Feb 5;14(2):e083582. doi: 10.1136/bmjopen-2023-083582. BMJ Open. 2024. PMID: 38316583 Free PMC article.
Cavernomas: to treat or not to treat?
Voase S, Robertson NP. Voase S, et al. Among authors: robertson np. J Neurol. 2024 Jan;271(1):618-620. doi: 10.1007/s00415-023-12115-0. Epub 2023 Dec 14. J Neurol. 2024. PMID: 38095721 Free PMC article. No abstract available.
398 results